Document:

EX-10.36

 Exhibit 10.36 

BIONANO GENOMICS, INC. 

NOTE PURCHASE AGREEMENT 

THIS NOTE PURCHASE AGREEMENT (this
“Agreement”) is made and entered into as of February 9, 2018, by and among BIONANO GENOMICS, INC., a Delaware corporation (the
“Company”), and the persons and entities listed on the Schedule of Investors attached hereto as EXHIBIT A (individually, an “Investor” and collectively, the
“Investors”). 
 RECITALS 

WHEREAS, in order to provide the Company with additional capital to conduct its
business, the Investors are willing to loan to the Company up to an aggregate amount of $15,960,000, subject to the conditions specified herein, and in exchange for such loan, the Company will issue convertible promissory notes to each Investor
as set forth herein. 
 AGREEMENT 

NOW THEREFORE, the parties to this Agreement, for good and valuable
consideration, the receipt and sufficiency of which is acknowledged and agreed, hereby agree as follows: 
 1. LOAN AMOUNT;
ISSUANCE OF NOTES. 
 (a) First Closing. Subject to the terms
of this Agreement, each Investor agrees, severally and not jointly, to lend to the Company at the First Closing (as defined below) the amount set forth under the heading “First Closing Loan Amount” opposite such Investor’s name on the
Schedule of Investors attached hereto as EXHIBIT A against the issuance and delivery by the Company to such Investor of a Convertible Promissory Note for such amount in the form attached hereto as
EXHIBIT B-1, with respect to the First Closing, and
EXHIBIT B-2, with respect to each Additional Closing (a “Note” and collectively with any other such notes issued pursuant
to this Agreement, the “Notes”). The Investors participating in the First Closing shall be referred to as the “First Closing Investors.” 

(b) Additional Closing(s). If the aggregate principal amount of the Notes purchased at the First Closing is less
than $15,960,000, then at any time on or before the earlier of the consummation of a Qualified Financing (as defined in the Notes) or March 15, 2018 (the “Outside Date”), or such later date as is approved by the
Investors holding at least 60% of the then-outstanding and unpaid principal and interest under all Notes (the “Requisite Investors”), the Company may sell up to the balance of the authorized Notes not sold at the First
Closing in one or more additional closings (each such closing, an “Additional Closing” and each of the First Closing and each Additional Closing, a “Closing”) to First Closing Investors or such other
“accredited investors” (as defined in Rule 501 of Regulation D under the Securities Act of 1933, as amended (the “Securities Act”)) as are acceptable to the Company and the Requisite Investors (“Eligible
Additional Investors”); provided, however, that the participation by the eligible investors up to the amounts set forth on EXHIBIT C attached hereto shall be considered acceptable to the Company
and the Requisite Investors. Each Eligible Additional Investor who elects to acquire Notes at an Additional Closing shall become a party to this Agreement by 

  
 1 

 
signing a counterpart signature page hereto (if such Eligible Additional Investor is not already a party hereto) and the Schedule of Investors attached hereto shall be amended to reflect the
amount each Eligible Additional Investor has agreed to lend the Company in the column entitled “Additional Closing Loan Amount” (each such amount and the First Closing Investors’ “First Closing Loan Amount,” a
“Loan Amount”). All loans made at an Additional Closing shall be made on the terms and conditions set forth in this Agreement, and the representations and warranties of the Company set forth in Section 3 hereof and the
representations and warranties set forth in Section 4 hereof of the Investors participating in such Additional Closing shall speak as of the date of such Additional Closing. Any Notes issued pursuant to this Section 1(b) shall be deemed to
be “Notes” for all purposes under this Agreement and any Eligible Additional Investor signing a counterpart signature page to this Agreement shall be deemed to be an “Investor” for all purposes under this Agreement. On each
Additional Closing Date (as defined below), each Eligible Additional Investor electing to participate in such Additional Closing (the “Additional Closing Investors”) shall lend to the Company at such Additional Closing the
amount set forth opposite its name under the column entitled “Additional Closing Loan Amount” on the Schedule of Investors attached hereto (as may be amended as described above) against the issuance and delivery by the Company of a Note
for such Loan Amount. 
 2. THE CLOSING. 

(a) Closing Dates. The closing of the purchase and sale of at least $6,000,000 of the Notes pursuant to
Section 1(a) hereof (the “First Closing”) shall be held within five days of the date of this Agreement at the offices of Cooley LLP, 4401 Eastgate Mall, SanDiego, California 92121, or at such other
time and place as the Company and the First Closing Investors shall agree. Any Additional Closing(s) shall be held at any time on or before the Outside Date as the Company and the Additional Closing Investors participating in such Additional Closing
shall agree (each such date, an “Additional Closing Date”). 
 (b) Delivery. At each
Closing (i) each Investor participating in such Closing will deliver to the Company, by check or wire transfer, funds in the amount set forth opposite each Investor’s name on EXHIBIT A; and (ii) the Company and
each Investor participating in such Closing shall deliver to each other a duly executed Note for such Investor’s applicable Loan Amount. 
 3.
REPRESENTATIONS AND WARRANTIES OF THE COMPANY. 

The Company hereby represents and warrants to each Investor as of the date of this Agreement as follows: 

(a) Organization, Good Standing and Qualification. The Company is a corporation duly incorporated, validly
existing and in good standing under the laws of the State of Delaware. The Company has the requisite corporate power and authority to own and operate its properties and assets, to execute and deliver this Agreement and the Notes (collectively, the
“Loan Documents”), to issue and sell the Securities (as defined below), to carry out the provisions of this Agreement and the other Loan Documents and to carry on its business as presently conducted and as presently proposed
to be conducted. The Company is duly 

  
 2 

 
qualified to do business and is in good standing as a foreign corporation in all jurisdictions in which the nature of its activities and of its properties (both owned and leased) makes such
qualification necessary, except for those jurisdictions in which failure to do so would not have a material adverse effect on the Company or its business. 

(b) Authorization. All corporate action on the part of the Company, its officers, directors and stockholders
necessary for the authorization, execution, delivery and performance of this Agreement and the other Loan Documents by the Company and the performance of the Company’s obligations hereunder and thereunder, including the issuance and delivery of
the Notes and the reservation of the Company’s Preferred Stock issuable pursuant to the Notes (together with the Notes, the “Securities”) has been taken or will be taken prior to the issuance of such Securities, as
applicable. The Loan Documents, when executed and delivered by the Company, shall constitute valid and binding obligations of the Company enforceable against the Company in accordance with their terms, subject to laws of general application relating
to bankruptcy, insolvency, the relief of debtors and, with respect to rights to indemnity, subject to federal and state securities laws. The Securities, when issued in compliance with the provisions of the Loan Documents, will be validly issued,
fully paid and nonassessable. The issuance of the Securities pursuant to the provisions of this Agreement will not violate any preemptive rights or rights of first refusal granted by the Company that will not be validly complied with or waived. The
Securities, when issued in compliance with the provisions of the Loan Documents, will be free of any liens or encumbrances, other than any liens or encumbrances created by or imposed upon the Investors through no action of the Company and
restrictions on transfer as set forth in the Loan Documents or under state and/or federal securities laws. 
 (c)
Consents. All consents, approvals, orders, or authorizations of, or registrations, qualifications, designations, declarations, or filings with, any governmental authority, stockholder or other third party, required on the part of the Company
in connection with the valid execution and delivery of the Loan Documents, the offer, sale or issuance of the Securities, or the consummation of any other transaction contemplated hereby shall have been obtained and will be effective at each
Closing, except for notices required or permitted to be filed with certain state and federal securities commissions, which notices will be filed on a timely basis in accordance with applicable law. 

(d) Compliance with Laws. To its knowledge, the Company is not in violation of any applicable statute, rule,
regulation, order or restriction of any domestic or foreign government or any instrumentality or agency thereof in respect of the conduct of its business or the ownership of its properties, which violation of which would materially and
adversely affect the business, assets, liabilities, financial condition, operations or prospects of the Company. 

(e) Compliance with Other Instruments. The Company is not in violation or default of any term of its Amended and
Restated Certificate of Incorporation or Amended and Restated Bylaws (the “Bylaws”), or of any provision of any mortgage, indenture or contract to which it is a party and by which it is bound or of any judgment, decree, order
or writ, other than such violation(s) that would not have a material effect on the Company. The execution, delivery and performance of this Agreement and the other Loan Documents, and the 

  
 3 

 
consummation of the transactions contemplated hereby or thereby will not result in any such violation or be in conflict with, or constitute, with or without the passage of time and giving of
notice, either a default under any such provision, instrument, mortgage, indenture contract, judgment, decree, order or writ or an event that results in the creation of any lien, charge or encumbrance upon any assets of the Company or the
suspension, revocation, impairment, forfeiture, or nonrenewal of any material permit, license, authorization or approval applicable to the Company, its business or operations or any of its assets or properties. Without limiting the foregoing, the
Company has obtained all waivers reasonably necessary with respect to any preemptive rights, rights of first refusal or similar rights, including any notice or offering periods provided for as part of any such rights, in order for the Company to
consummate the transactions contemplated hereunder without any third party obtaining any rights to cause the Company to offer or issue any securities of the Company as a result of the consummation of the transactions contemplated hereunder. 

(f) Offering. Assuming the accuracy of the representations and warranties of the Investors contained in
Section 4 hereof, the offer, issue, and sale of the Securities are and will be exempt from the registration and prospectus delivery requirements of the Securities Act, and have been registered or qualified (or are exempt from registration and
qualification) under the registration, permit, or qualification requirements of all applicable state securities laws. 

(g) Disclosure. The Company has made available to the Investors all the information reasonably available to the
Company that the Investors have requested. No representation or warranty of the Company contained in this Agreement and no certificate furnished or to be furnished to Investors at the Closing as required by this Agreement contains any untrue
statement of a material fact or, to the Company’s knowledge, omits to state a material fact necessary in order to make the statements contained herein or therein not misleading in light of the circumstances under which they were made. It is
understood that this representation is qualified by the fact that the Company has not delivered to the Investors, and has not been requested to deliver, a private placement or similar memorandum or any written disclosure of the types of information
customarily furnished to purchasers of securities. 
 4. REPRESENTATIONS AND WARRANTIES OF
THE INVESTORS. 
 Each Investor, severally and not jointly, hereby represents and warrants
to the Company as follows: 
 (a) Purchase for Own Account. Such Investor represents that it is acquiring the
Securities solely for its own account and beneficial interest for investment and not for sale or with a view to distribution of the Securities or any part thereof, has no present intention of selling (in connection with a distribution or otherwise),
granting any participation in, or otherwise distributing the same, and does not presently have reason to anticipate a change in such intention. 

(b) Information and Sophistication. Without lessening or obviating the representations and warranties of the
Company set forth in Section 3, such Investor (i) acknowledges that it has received all the information it has requested from the Company and it considers necessary or appropriate for deciding whether to acquire the Securities,
(ii) represents 

  
 4 

 
that it has had an opportunity to ask questions and receive answers from the Company regarding the terms and conditions of the offering of the Securities and to obtain any additional information
necessary to verify the accuracy of the information given such Investor and (iii) further represents that it has such knowledge and experience in financial and business matters that it is capable of evaluating the merits and risk of this
investment. 
 (c) Ability to Bear Economic Risk. Such Investor acknowledges that investment in the Securities
involves a high degree of risk, and represents that it is able, without materially impairing its financial condition, to hold the Securities for an indefinite period of time and to suffer a complete loss of its investment. 

(d) Further Limitations on Disposition. Without in any way limiting the representations set forth above, such
Investor further agrees not to make any disposition of all or any portion of the Securities unless and until: 
 (i) There
is then in effect a registration statement under the Securities Act covering such proposed disposition and such disposition is made in accordance with such registration statement; or 

(ii) (A) The transferee has agreed in writing to be bound by the terms of the Loan Documents (except as provided in the last
sentence of this Section 4(d)(ii)), (B) such Investor shall have notified the Company of the proposed disposition and shall have furnished the Company with a detailed statement of the circumstances surrounding the proposed disposition, and
(C) if reasonably requested by the Company, such Investor shall have furnished the Company with an opinion of counsel, reasonably satisfactory to the Company, that such disposition will not require registration of such shares under the
Securities Act. It is agreed that the Company will not require opinions of counsel for transactions made pursuant to Rule 144 of the Securities Act, except in unusual circumstances. After the Company’s first firm commitment underwritten public
offering of its Common Stock registered under the Securities Act (the “Initial Offering”), the Company will not require the transferee to be bound by the terms of this Agreement. 

(e) Notwithstanding the provisions of subsection (d) above, no such restriction shall apply to a transfer by an
Investor that is (i) a partnership transferring to its partners or former partners in accordance with partnership interests, (ii) a corporation transferring to a wholly-owned subsidiary or a parent corporation that owns all of the
capital stock of the Investor, (iii) a limited liability company transferring to its members or former members in accordance with their interests in the limited liability company, (iv) an Investor transferring to its affiliated venture
capital fund or (v) an individual transferring to the Investor’s family member or trust for the benefit of an individual Investor (each such transferee, an “Affiliate” of such Investor); provided, that in
each case the Affiliate will agree in writing to be subject to the terms of this Agreement to the same extent as if such Affiliate were an original Investor hereunder (except as provided in the last sentence of Section 4(d)(ii)). 

(f) Each Investor understands and agrees that all certificates evidencing the Securities to be issued to such Investor
shall be stamped or otherwise imprinted with legends 

  
 5 

 
substantially similar to the following (in addition to any legend required under the Company’s Bylaws and applicable state securities laws): 

THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE
“ACT”), AND MAY NOT BE OFFERED, SOLD OR OTHERWISE TRANSFERRED, ASSIGNED, PLEDGED OR HYPOTHECATED UNLESS AND UNTIL REGISTERED UNDER THE ACT OR UNLESS THE COMPANY HAS RECEIVED AN OPINION OF COUNSEL SATISFACTORY TO THE COMPANY
AND ITS COUNSEL THAT SUCH REGISTRATION IS NOT REQUIRED. 
 THE SALE, PLEDGE, HYPOTHECATION OR TRANSFER OF THE SECURITIES
REPRESENTED BY THIS CERTIFICATE IS SUBJECT TO THE TERMS AND CONDITIONS OF A CERTAIN NOTE PURCHASE AGREEMENT BY AND BETWEEN THE STOCKHOLDER AND THE COMPANY. COPIES OF SUCH AGREEMENT MAY BE OBTAINED UPON WRITTEN REQUEST TO THE SECRETARY OF THE
COMPANY. 
 (g) Accredited Investor Status. Each Investor is an “accredited investor” as such term
is defined in Rule 501 under the Securities Act. 
 (h) Foreign Investor. Each Investor that is a foreign
person or a U.S. subsidiary or affiliate of a foreign parent company (a “Foreign Investor”) shall notify the Company of its status as a Foreign Investor and the aggregate number of shares of the Company’s capital
stock and any security held, directly or indirectly, by the Foreign Investor that is convertible into shares of the Company’s capital stock. 
 5.
MARKET STAND-OFF AGREEMENT. 

(a) Each Investor hereby agrees that such Investor shall not sell, transfer, make any short sale of, grant any option
for the purchase of, or enter into any hedging or similar transaction with the same economic effect as a sale, any Common Stock (or other securities) of the Company held by such Investor (other than those included in the registration) during the 180-day period following the effective date of the Initial Offering (or such longer period as the underwriters or the Company shall in good faith request in order to facilitate compliance with NASD Rule 2711 or NYSE
Member Rule 472 or any successor or similar rule or regulation); provided, that, all officers and directors of the Company are bound by and have entered into similar agreements. 

(b) Each Investor agrees to execute and deliver such other agreements as may be reasonably requested by the Company or
the underwriter that are consistent with the Investor’s obligations under Section 5(a) or that are necessary to give further effect thereto. In addition, if requested by the Company or the representative of the underwriters of Common
Stock (or other securities) of the Company, each Investor shall provide, within 10 days of such request, such information as may be required by the Company or such representative in 

  
 6 

 
connection with the completion of any public offering of the Company’s securities pursuant to a registration statement filed under the Securities Act. The obligations described in
Section 5(a) and this Section 5(b) shall not apply to (i) a registration statement relating to any employee benefit plan or (ii) with respect to any corporate reorganization or transaction under Rule 145 of the Securities
Act, any registration statements related to the issuance or resale of securities issued in such a transaction or (iii) a registration related to stock issued upon conversion of debt securities. The Company may impose stop-transfer instructions
with respect to the shares of Common Stock (or other securities) subject to the foregoing restriction until the end of said day period. Each Investor agrees that any transferee of any Securities shall be bound by this Section 5. The
underwriters of the Company’s stock are intended third party beneficiaries of this Section 5 and shall have the right, power and authority to enforce the provisions hereof as though they were a party hereto. 

6. SECURITY. 

6.1 Ranking. Except for the Existing Loan, each Note shall be senior in all respects (including the right of
payment) to all other indebtedness of the Company, now or hereafter existing, provided that each Note will rank pari passu with the other Notes issued by the Company. 

6.2 Senior Indebtedness. The indebtedness evidenced by this Agreement is subordinated in right of payment to the
prior payment in full of all amounts due in connection with that certain Loan and Security Agreement by and among the Company and Western Alliance Bank, as amended on December 9, 2016 (the “Existing Loan”).
Furthermore, the indebtedness evidenced under this Agreement is subject to the terms of the Subordination Agreement, in the form attached hereto as Exhibit D (the “Subordination Agreement”), to be entered into by and
among the Company, Western Alliance Bank and the Investors, and in the event of any conflict between the terms hereof and the Subordination Agreement, the respective terms of the Subordination Agreement shall prevail. 

7. USE OF PROCEEDS. The Company shall use the proceeds received from
its issuance of the Notes solely for its working capital, capital expenditure, marketing and operational expenses, subject to Section 8 below. 

8. NEGATIVE COVENANTS. In addition to the rights of the Investors in the
Company’s currently effective certificate of incorporation and agreements amongst stockholders, without the prior written consent of the Investors holding a majority of the then-outstanding and unpaid principal and interest under all Notes, the
Company shall not do any of the following: 
 8.1 repay or amend the terms of existing indebtedness, other than the
Existing Loan in accordance with its terms; and 
 8.2 create or incur or authorize the creation or incurrence of any
new indebtedness (or any increase of any existing indebtedness as of the date hereof). 
 9. FURTHER
ASSURANCES. The Company and each Investor agree and covenant that at any time and from time to time it will promptly execute and deliver to each other such further

  
 7 

 
instruments and documents and take such further action as each of the parties hereto may reasonably require in order to carry out the full intent and purpose of this Agreement. 

10. MISCELLANEOUS. 

(a) Binding Agreement. The terms and conditions of this Agreement shall inure to the benefit of and be
binding upon the respective successors and assigns of the parties. Nothing in this Agreement, express or implied, is intended to confer upon any third party any rights, remedies, obligations, or liabilities under or by reason of this Agreement,
except as expressly provided in this Agreement. 
 (b) Governing Law. This Agreement shall be governed by and
construed under the laws of the State of California in all respects as such laws are applied to agreements among California residents entered into and performed entirely within California, without giving effect to conflict of law principles thereof.
The parties agree that any action brought by either party under or in relation to this Agreement, including without limitation to interpret or enforce any provision of this Agreement, shall be brought in, and each party agrees to and does hereby
submit to the jurisdiction and venue of, any state or federal court located in the State of California. 
 (c)
Counterparts; Facsimile and PDF. This Agreement may be executed in any number of counterparts, each of which shall be an original, but all of which together shall constitute one instrument. Signatures delivered by facsimile or electronic
transmission shall have the same effect as originals. 
 (d) Expenses; Attorney’s Fees.
Each party shall pay all costs and expenses that it incurs with respect to the negotiation, execution and delivery of the Agreement. If any action at law or in equity (including arbitration) is necessary to enforce or interpret the terms of any of
the Loan Documents, the prevailing party shall be entitled to reasonable attorneys’ fees, costs and necessary disbursements in addition to any other relief to which such party may be entitled. 

(e) Titles and Subtitles. The titles and subtitles used in this Agreement are used for convenience only and are
not to be considered in construing or interpreting this Agreement. 
 (f) Notices. All notices required or
permitted hereunder or under the other Loan Documents shall be in writing and shall be deemed effectively given: (i) upon personal delivery to the party to be notified, (ii) when sent by confirmed electronic mail, telex or facsimile if
sent during normal business hours of the recipient, if not, then on the next business day, (iii) five days after having been sent by registered or certified mail, return receipt requested, postage prepaid, or (iv) one day after deposit
with a nationally recognized overnight courier, specifying next day delivery, with written verification of receipt. All communications shall be sent to the Company at the address as set forth on the signature page hereof and the Investors at the
addresses set forth on Exhibit A attached hereto or at such other address or electronic mail address as the Company or an Investor may designate by 10 days advance written notice to the other parties hereto. 

  
 8 

 (g) Amendment; Waiver. No amendment or waiver of any provision of
this Agreement shall be effective unless in writing and approved by the Company and the Requisite Investors. 
 (h)
Delays or Omissions. It is agreed that no delay or omission to exercise any right, power or remedy accruing to each Investor, upon any breach or default of the Company under this Agreement or any other Loan Document shall impair any such
right, power or remedy, nor shall it be construed to be a waiver of any such breach or default, or any acquiescence therein, or of or in any similar breach or default thereafter occurring; nor shall any waiver of any single breach or default be
deemed a waiver of any other breach or default theretofore or thereafter occurring. It is further agreed that any waiver, permit, consent or approval of any kind or character by Investor of any breach or default under this Agreement, or any waiver
by any Investor of any provisions or conditions of this Agreement must be in writing and shall be effective only to the extent specifically set forth in writing and that all remedies, either under this Agreement, or by law or otherwise afforded to
the Investor, shall be cumulative and not alternative. 
 (i) Entire Agreement. This Agreement and the
Exhibits hereto and thereto constitute the full and entire understanding and agreement between the parties with regard to the subjects hereof and no party shall be liable or bound to any other party in any manner by any representations, warranties,
covenants and agreements except as specifically set forth herein. 
 (j) Severability. Each of the
provisions of this Agreement is severable. If any such provision is held to be or becomes illegal, invalid or unenforceable in any respect under the law of any jurisdiction, it shall have no effect on any other provisions of this Agreement and
(a) the parties shall use their reasonable efforts to replace such provision with a suitable and equitable provision in order to carry out as closely as is possible, so far as may be valid and enforceable, the intent and purpose of such
illegal, invalid or unenforceable provision and (b) the remainder of this Agreement and the application of such provision to other persons or circumstances shall not be affected by such illegality, invalidity or unenforceability, nor shall such
illegality, invalidity or unenforceability affect the validity or enforceability of such provision, or the application thereof, in any other jurisdiction. 

(k) Corporate Securities Law. THE SALE OF THE SECURITIES WHICH ARE THE SUBJECT OF THIS AGREEMENT HAS NOT BEEN
QUALIFIED WITH THE COMMISSIONER OF CORPORATIONS OF THE STATE OF CALIFORNIA AND THE ISSUANCE OF THE SECURITIES OR THE PAYMENT OR RECEIPT OF ANY PART OF THE CONSIDERATION THEREFOR PRIOR TO THE QUALIFICATION IS UNLAWFUL, UNLESS THE SALE OF SECURITIES
IS EXEMPT FROM THE QUALIFICATION BY SECTION 25100, 25102 OR 25105 OF THE CALIFORNIA CORPORATIONS CODE. THE RIGHTS OF ALL PARTIES TO THIS AGREEMENT ARE EXPRESSLY CONDITIONED UPON THE QUALIFICATION BEING OBTAINED UNLESS THE SALE IS SO EXEMPT.

 [REMAINDER OF THIS PAGE INTENTIONALLY LEFT BLANK] 

  
 9 

 IN WITNESS WHEREOF, the
parties have executed this NOTE PURCHASE AGREEMENT as of the date first written above. 

 

			
	COMPANY:
	
	BIONANO GENOMICS, INC.
		
	By:	 	 /s/ R. Erik Holmlin, Ph.D.

	Name: 	 	 R. Erik Holmlin, Ph.D.

	Title:	 	 Chief Executive Officer

	  
 Address for notice:

	
	 9640 Towne Centre Dr, #100

	 San Diego, CA 92121

	 

 [SIGNATURE PAGE TO NOTE
PURCHASE AGREEMENT] 

 IN WITNESS WHEREOF, the
parties have executed this NOTE PURCHASE AGREEMENT as of the date first written above. 

 

			
	INVESTOR:
	
	 ALEXANDRIA VENTURE INVESTMENTS, LLC

	By:	 	 Alexandria Real Estate Equities, Inc.,

its managing member

		
	By:	 	 /s/ Aaron Jacobson

	Name:	 	 Aaron Jacobson

	Title:	 	 VP – Corporate Counsel

 [SIGNATURE PAGE TO NOTE
PURCHASE AGREEMENT] 

 IN WITNESS WHEREOF, the
parties have executed this NOTE PURCHASE AGREEMENT as of the date first written above. 

 

			
	INVESTORS:
	
	DOMAIN PARTNERS VIII, L.P.
	By: One Palmer Square Associates VIII, L.L.C., its General Partner
		
	By:	 	 /s/ Lisa A Kraeutler

	Name:	 	 Lisa A. Kraeutler

	Title:	 	 Attorney-in-fact

	
	DP VIII ASSOCIATES, L.P.
	By: One Palmer Square Associates VIII, L.L.C., its General Partner
		
	By:	 	 /s/ Lisa A Kraeutler

	Name:	 	 Lisa A. Kraeutler

	Title:	 	 Attorney-in-fact

 [SIGNATURE PAGE TO NOTE
PURCHASE AGREEMENT] 

 IN WITNESS WHEREOF, the
parties have executed this NOTE PURCHASE AGREEMENT as of the date first written above. 

 

			
	INVESTOR:
	
	ETP GLOBAL FUND, LP
	By: Emerging Technology Partners LLC, its General Partner
		
	By:	 	 /s/ James K. Hu

	Name:	 	 James K. Hu

	Title:	 	 Managing Director

 [SIGNATURE PAGE TO NOTE
PURCHASE AGREEMENT] 

 IN WITNESS WHEREOF, the
parties have executed this NOTE PURCHASE AGREEMENT as of the date first written above. 

 

			
	INVESTOR:
	
	LC HEALTHCARE FUND I, L.P.
		
	By:	 	 /s/ Jafar Wang

	Name:	 	 Jafar Wang

	Title:	 	 Managing Director

 [SIGNATURE PAGE TO NOTE
PURCHASE AGREEMENT] 

 IN WITNESS WHEREOF, the
parties have executed this NOTE PURCHASE AGREEMENT as of the date first written above. 

 

			
	INVESTOR:
	
	MONASHEE INVESTMENT MANAGEMENT, LLC
		
	By:	 	 /s/ Jeff Muller

	Name:	 	 Jeff Muller

	Title:	 	 CCO

 [SIGNATURE PAGE TO NOTE
PURCHASE AGREEMENT] 

 IN WITNESS WHEREOF, the parties have executed
this NOTE PURCHASE AGREEMENT as of the date first written above. 
  

	
	INVESTOR:
	
	ROBERT AUSTIN
	
	 /s/ Robert Austin

 [SIGNATURE PAGE TO NOTE
PURCHASE AGREEMENT] 

 IN WITNESS WHEREOF, the
parties have executed this NOTE PURCHASE AGREEMENT as of the date first written above. 

 

			
	INVESTOR:
	
	ROSY SHINE LIMITED
		
	By:	 	 /s/ Hao Ouyang

	Name:	 	 Hao Ouyang

	Title:	 	 Director

 [SIGNATURE PAGE TO NOTE
PURCHASE AGREEMENT] 

 LIST OF EXHIBITS 
  

			
		
	 Exhibit A:
	 	 Schedule of Investors

		
	 Exhibit B-1:
	 	 Form of Convertible Promissory Note at the First Closing

		
	 Exhibit B-2:
	 	 Form of Convertible Promissory Note at each Additional Closing

		
	 Exhibit C:
	 	 List of Approved Additional Investors

		
	 Exhibit D:
	 	 Form of Subordination Agreement

 EXHIBIT A 

SCHEDULE OF INVESTORS 

FIRST CLOSING: 
  

					
	 NAME &
ADDRESS
	  	FIRST CLOSING LOAN
AMOUNT	 
	 ROSY SHINE LIMITED

Legend Capital, 10F, Tower A, Raycom Infotech Park, No.2

Kexueyuan South Road, Zhongguancun, Haidian District

Beijing 100190 PRC
	  	$	5,000,000	 
	 LC HEALTHCARE FUND I, L.P.

Legend Capital, 10F, Tower A, Raycom Infotech Park, No.2

Kexueyuan South Road, Zhongguancun, Haidian District

Beijing 100190 PRC
	  	$	3,460,000	 
	 ETP GLOBAL FUND, LP

9620 Medical Center Drive, #200

Rockville, MD 20850
	  	$	3,000,000	 
	 DOMAIN PARTNERS VIII, L.P.

One Palmer Square, Suite 515

Princeton, NJ 08542
	  	$	1,488,952	 
	 DP VIII ASSOCIATES, L.P.

One Palmer Square, Suite 515

Princeton, NJ 08542
	  	$	11,048	 
	 ALEXANDRIA VENTURE INVESTMENTS, LLC

Attn: Krystal Garcia

385 Colorado Blvd., Suite 299

Pasadena, CA 91101
	  	$	250,000	 
	 MONASHEE INVESTMENT MANAGEMENT, LLC

Attn: Tom Wynn

125 High Street

High Street Tower 28

Boston, MA 02110
	  	$	161,375	 
	 ROBERT AUSTIN

135 Harris Road

Princeton, NJ 08540
	  	$	757	 
	 Total:
	  	$	13,372,132.00	 

 ADDITIONAL CLOSING: 

 

			
	 NAME &
ADDRESS
	  	ADDITIONAL CLOSING
LOAN AMOUNT
	 [TBD]
	  	[TBD]

  
 A-1 

 EXHIBIT B-1 

FORM OF CONVERTIBLE PROMISSORY NOTE AT THE FIRST CLOSING 

 THIS NOTE AND THE SECURITIES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES
ACT OF 1933, AS AMENDED (THE “ACT”), AND MAY NOT BE OFFERED, SOLD OR OTHERWISE TRANSFERRED, ASSIGNED, PLEDGED OR HYPOTHECATED UNLESS AND UNTIL REGISTERED UNDER THE ACT OR UNLESS THE COMPANY HAS RECEIVED AN OPINION OF
COUNSEL SATISFACTORY TO THE COMPANY AND ITS COUNSEL THAT SUCH REGISTRATION IS NOT REQUIRED.  
 THE SALE, PLEDGE, HYPOTHECATION OR
TRANSFER OF THIS NOTE AND THE SECURITIES ISSUABLE HEREUNDER IS SUBJECT TO THE TERMS AND CONDITIONS OF A CERTAIN NOTE PURCHASE AGREEMENT BY AND BETWEEN THE HOLDER AND THE COMPANY. COPIES OF SUCH AGREEMENT MAY BE OBTAINED UPON WRITTEN REQUEST TO THE
SECRETARY OF THE COMPANY. 
 THIS NOTE (AND ALL PAYMENT AND ENFORCEMENT PROVISIONS HEREIN) (THE
“NOTE”) IS AN UNSECURED OBLIGATION OF THE COMPANY AND IS SUBJECT TO THE TERMS OF A SUBORDINATION AGREEMENT DATED AS OF FEBRUARY [7], 2018, BY AND AMONG THE COMPANY, THE HOLDER, WESTERN ALLIANCE BANK AND OTHER PARTIES
THERETO (THE “SUBORDINATION AGREEMENT”). IN THE EVENT OF ANY INCONSISTENCY BETWEEN THIS NOTE AND THE SUBORDINATION AGREEMENT, THE TERMS OF THE SUBORDINATION AGREEMENT SHALL CONTROL. 

BIONANO GENOMICS, INC. 

CONVERTIBLE PROMISSORY NOTE 
  

			
	 $[___________]
	  	 [____________], 2018

San Diego, California

 FOR VALUE RECEIVED,
BIONANO GENOMICS, INC., a Delaware corporation (the “Company”), hereby promises to pay to the order of [______________] (the
“Holder”), the principal sum of up to $[_________] (the “Loan Amount”), together with accrued and unpaid interest thereon, each due and payable on the date and in the manner set forth below. 

This Note is part of a series of similar notes (collectively, the “Notes”) issued pursuant to the terms of that
certain Note Purchase Agreement dated as of February [8], 2018, among the Company and the Investors listed on the Schedule of Investors attached thereto as Exhibit A (as may be amended from time to time, the “Purchase
Agreement”). Capitalized terms used and not otherwise defined herein shall have the meanings given them in the Purchase Agreement. 

1. Maturity Date. Unless converted into equity securities of the Company or repaid pursuant to Sections 5 or 6 hereof, subject
to the provisions of Sections 6 and 9 below, the entire outstanding principal balance and all unpaid accrued interest hereof shall, upon written election of the Requisite Investors, become fully due and payable to the Holder on September 30,
2018, or such later date as is approved by the Requisite Investors (the “Maturity Date”). 

  
 1. 

 2. Interest. Interest shall accrue on the outstanding principal amount hereof from
the date of this Note until payment or conversion in full, which interest shall be payable at the rate of 8% per annum or the Highest Lawful Rate (as defined below), whichever is less. Interest shall be due and payable on the Maturity Date, and
shall be calculated on the basis of a 365-day year for the actual number of days elapsed. 

3. Payment. Unless the indebtedness outstanding under this Note is converted in accordance with Sections 5 hereof, payment shall
be made in lawful money of the United States to the Holder at the Company’s principal offices or, at the option of the Holder, at such other place in the United States as Holder shall have designated by written notice to the Company. All
payments shall be applied first to accrued interest and thereafter to principal and shall be made pro rata among all holders of Notes. 

4. Prepayment. Except as provided in Sections 6 and 9, prepayment by the Company of principal or accrued interest outstanding
under this Note may be made only with the prior written consent of the Requisite Investors, and provided that any such prepayment shall be made on a pro rata basis among all of the Notes. 

5. Conversion. 

5.1 Conversion at Qualified Financing. Upon the closing of a Qualified Financing (as defined below) before
the Maturity Date, if this Note has not been prepaid or converted prior to closing of the Qualified Financing, then all unpaid principal and accrued interest outstanding under this Note (the “Conversion Amount”) shall
automatically convert into that number of shares of the Preferred Stock sold by the Company in the Qualified Financing as is equal to the quotient of (x) the Conversion Amount as of the date immediately prior to the initial closing of such
Qualified Financing divided by (y) the Conversion Price (as defined below), and on the other terms and conditions provided to investors in the Qualified Financing; provided, however, that such Preferred Stock issued to the Holder shall
be participating Preferred Stock (for clarity, with participation by the holders of such Preferred Stock being on a pro rata and as-converted basis, together with the holders of the Company’s Common Stock
and any other series of the Company’s participating Preferred Stock, in any remaining proceeds following the payment of all liquidation preferences) and the liquidation preference of each share of such Preferred Stock shall be the greater of
(a) the liquidation preference of the Preferred Stock sold by the Company in the Qualified Financing and (b) two and one quarter times the original issue price of such Preferred Stock. “Qualified Financing” shall
mean the first equity financing following the date of this Note involving the sale by the Company of its Preferred Stock in which the Company receives an aggregate of at least $15,000,000 in cumulative gross proceeds, excluding conversion of the
Conversion Amount under this Note and all other Notes in connection with such financing. “Conversion Price” shall mean 75% of the lowest per share cash purchase price of the Preferred Stock sold by the Company in the
Qualified Financing. 
 5.2 Conversion at Initial Public Offering. If at any time prior to the Maturity Date
the Company completes an initial public offering of its Common Stock pursuant to an effective registration statement under the Securities Act of 1933, as amended (the “IPO”), if this Note has not been prepaid or converted
prior to the closing of the IPO, then the Company 

  
 2. 

 
shall provide to the Holder at least 10 days written notice prior to the closing of the IPO, and the Conversion Amount shall automatically convert into that number of shares of Common Stock as is
equal to the quotient of (x) the Conversion Amount as of the date immediately prior to the closing of the IPO divided by (y) 75% of the per share cash purchase price of the Common Stock to the public in the IPO. 

5.3 Optional Conversion at Maturity Date. If this Note has not been previously converted pursuant to a Qualified
Financing or an IPO, then, effective as of the Maturity Date, upon written election of the Requisite Investors, the Conversion Amount shall automatically convert into a number of shares of Series D-2 Preferred
(as defined below) as is equal to the quotient of (x) the Conversion Amount as of the Maturity Date divided by (y) the price per share equal to $60,000,000 divided by the aggregate number of outstanding shares of the Company’s Common
Stock (the “Common Stock”) as of the Maturity Date (assuming, for purposes of calculating such number of outstanding shares, conversion of all securities convertible into Common Stock and exercise of all outstanding options
and warrants (whether vested or unvested) and including all shares reserved for future issuance under authorized but unissued options, but excluding the shares of equity securities of the Company issuable upon conversion of the Notes). Any
election by the Requisite Investors to convert the Notes pursuant to this Section 5.3 will be made in writing and delivered to the Company at least five days prior to the Maturity Date. “Series D-2 Preferred” shall mean a newly designated series of Preferred Stock of the Company with rights and preferences equivalent to the most senior then outstanding series of Preferred Stock, which shall be
participating Preferred Stock (for clarity, with participation by the holders of such preferred stock being on a pro rata and as-converted basis, together with the holders of the Company’s Common Stock
and any other series of the Company’s participating Preferred Stock, in any remaining proceeds following the payment of all liquidation preferences) and the liquidation preference of each share of such Preferred Stock shall be equal to two and
one quarter times the original issue price of such Preferred Stock. 
 6. Liquidation Event or Deemed Liquidation Event. If at
any time prior to the Maturity Date there occurs a Liquidation Event or Deemed Liquidation Event (each as defined in the Company’s Eighth Amended and Restated Certificate of Incorporation, as amended (the “Charter”)), if
this Note has not been prepaid or converted prior to the closing of such Liquidation Event or Deemed Liquidation Event, then the Company shall provide to the Holder at least 10 days written notice prior to the closing of such Liquidation Event or
Deemed Liquidation Event, and the Notes will become payable contingent upon and concurrently with the successful closing of such Liquidation Event or Deemed Liquidation Event, for an amount equal to (x) 250% of the outstanding principal amount
of such Note plus (y) all unpaid interest accrued hereunder as of the date of the Liquidation Event or Deemed Liquidation Event. Notwithstanding the foregoing, none of the following events shall be deemed to be a Liquidation Event or
Deemed Liquidation Event: any transaction or series of transactions principally for bona fide equity financing purposes in which cash is received by the Company or any successor or indebtedness of the Company is cancelled or converted or a
combination thereof. 
 7. Reservation of Shares. In case the Company does not, at the time of conversion of this Note, have
sufficient authorized but unissued shares of stock of whatever class or series 

  
 3. 

 
necessary to properly give effect to the conversion of the Note as outlined above, the Company shall promptly (a) give notice to the Holder and (b) subject to receipt of requisite
stockholder approvals (the failure of which shall not be deemed a breach or default under this Note, provided that the Company shall make good faith best efforts to secure such approvals), amend its charter documents so as to provide for adequate
shares of authorized stock to the appropriate class and/or series. 
 8. Termination of Rights. All rights with respect
to this Note shall terminate upon a payment or conversion of the Conversion Amount in full, whether or not this Note has been surrendered. 

9. Default. Each of the following events shall be an “Event of Default” hereunder: 

(a) The Company fails to pay timely any of the principal amount due under this Note on the date the same becomes due and
payable or any accrued interest or other amounts due under this Note on the date the same becomes due and payable; 

(b) The Company commits a material breach of the representations, warranties or covenants in the Purchase Agreement or
any other Loan Document; 
 (c) The Company ceases to conduct or carry out the core business of the Company
substantially as now conducted; 
 (d) The Company files a petition or action for relief under any bankruptcy,
insolvency or moratorium law or any other law for the relief of, or relating to, debtors, now or hereafter in effect, or makes any assignment for the benefit of creditors or takes any action in furtherance of any of the foregoing; 

(e) An involuntary petition is filed against the Company (unless such petition is dismissed or discharged within 60
days) under any bankruptcy statute now or hereafter in effect, or a custodian, receiver, trustee, assignee for the benefit of creditors (or other similar official) is appointed to take possession, custody or control of any property of the Company;

 (f) The occurrence of an “event of default” or other event or circumstance under any agreement
evidencing any indebtedness for borrowed money which results in the acceleration of, or entitles the holder of such indebtedness to accelerate, the maturity thereof; 

(g) The appointment of a receiver to foreclose the Company’s assets or the initiation of judicial or non-judicial proceedings to enforce collateral rights (such as foreclosure or sale of the Company’s assets) under any agreement evidencing any indebtedness for borrowed money; or 

(h) The dissolution or winding up of the Company, the suspension of its operations, or the taking of any corporate
action to effect any of the foregoing. 
 Upon the occurrence of an Event of Default, all unpaid principal, accrued interest and other
amounts owing hereunder shall automatically, be immediately due, payable and collectible by 

  
 4. 

 
the Holder pursuant to applicable law. Subject to the provisions hereof, the Holder shall have all rights and may exercise any remedies available to it under law, successively or concurrently.

 10. Fractional Shares. No fractional shares shall be issued upon conversion of this Note, and instead any fractional shares
shall be rounded down to the nearest whole share. 
 11. No Impairment. Except and to the extent as waived or consented to by
the Requisite Investors in accordance with Section 17 below, the Company will not, by amendment of the Charter or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of any debt
or equity securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms to be observed or performed hereunder by the Company, but will at all times in good faith assist in the carrying out of all
the provisions of this Note in order to protect the rights of Holder hereunder against impairment. 
 12. Highest Lawful Rate.
Anything herein to the contrary notwithstanding, if during any period for which interest is computed hereunder, the amount of interest computed on the basis provided for in this Note, together with all fees, charges, and other payments or rights
which are treated as interest under applicable law, as provided for herein or in any other document executed in connection herewith, would exceed the amount of such interest computed on the basis of the Highest Lawful Rate (as defined below), the
Company shall not be obligated to pay, and the Holder shall not be entitled to charge, collect, receive, reserve, or take, interest in excess of the Highest Lawful Rate, and during any such period the interest payable hereunder shall be computed on
the basis of the Highest Lawful Rate. “Highest Lawful Rate” means the maximum non-usurious rate of interest, as in effect from time to time, which may be charged, contracted for,
reserved, received, or collected by the Holder in connection with this Note under applicable law. In accordance with this section, any amounts received in excess of the Highest Lawful Rate shall be applied towards the prepayment of principal then
outstanding. 
 13. Security 

13.1 Ranking. Except for the Existing Loan, this Note shall be senior in all respects (including the right of
payment) to all other indebtedness of the Company, now or hereafter existing, provided that this Note will rank pari passu with the other Notes issued by the Company. 

13.2 Senior Indebtedness. The indebtedness evidenced by this Note is subordinated in right of payment to the
prior payment in full of all amounts due in connection with that certain Loan and Security Agreement dated as of March 8, 2016, by and between the Company and Western Alliance Bank, as amended on December 9, 2016, May 2, 2017 and
November 20, 2017 (as may be amended from time to time, the “Existing Loan”). Furthermore, the indebtedness evidenced under this Note is subject to the terms of the Subordination Agreement by and among the Company,
Western Alliance Bank and the Holder, and in the event of any conflict between the terms hereof and the Subordination Agreement, the respective terms of the Subordination Agreement shall prevail. 

14. More Favorable Terms. So long as any portion of the Loan Amount and/or any accrued interest thereon remains unpaid and
outstanding, if after the date hereof the Company 

  
 5. 

 
issues any convertible promissory notes to or enters into any note purchase agreement with any lender having any terms and/or conditions that are, individually or in the aggregate, more favorable
than the terms and conditions granted to the Holder under this Note or any other Loan Document, then the Holder shall have the right to require the Company to amend this Note or any other Loan Document to reflect substantially equivalent
terms and conditions in favor of the Holder. 
 15. Waiver. Subject to any other provision herein or in the other Loan
Documents, the Company hereby waives demand, notice, presentment, protest and notice of dishonor. 
 16. Governing Law. This
Note shall be governed by and construed under the laws of the State of California in all respects as such laws are applied to agreements among California residents entered into and performed entirely within California, without giving effect to
conflict of law principles thereof. 
 17. Successors and Assigns. Neither this Note nor any rights hereunder shall be
transferable by the Holder without the prior written consent of the Company, except to an Affiliate of the Holder in accordance with the terms of the Purchase Agreement. Subject to the foregoing, the provisions of this Note shall inure to the
benefit of and be binding on any successor to the Company and shall extend to any Holder hereof. 
 18. Amendment; Waiver. Any
term of this Note may be amended or waived with the written consent of the Company and the Requisite Investors. Any such amendment or waiver so effected by the Company and the Requisite Investors shall be binding on the Holder. 

19. Agreement to be Bound. As a condition to the conversion of the Note, the Holder, if requested by the Company, shall agree in
writing to be fully bound by any purchase agreement or investors rights, stockholders, voting or similar agreements applicable to the holders of the Company’s capital stock. 

20. Expenses; Attorney’s Fees. Each party shall pay all costs and expenses that it incurs with respect to the negotiation,
execution and delivery of the Agreement. If any action at law or in equity (including arbitration) is necessary to enforce or interpret the terms of any of the Loan Documents, the prevailing party shall be entitled to reasonable attorneys’
fees, costs and necessary disbursements in addition to any other relief to which such party may be entitled. 
 21.
Severability. Each of the provisions of this Note is severable. If any such provision is held to be or becomes illegal, invalid or unenforceable in any respect under the law of any jurisdiction, it shall have no effect on any other provisions
of this Note and (a) the parties shall use their reasonable efforts to replace such provision with a suitable and equitable provision in order to carry out as closely as is possible, so far as may be valid and enforceable, the intent and
purpose of such illegal, invalid or unenforceable provision and (b) the remainder of this Note and the application of such provision to other persons or circumstances shall not be affected by such illegality, invalidity or unenforceability, nor
shall such illegality, invalidity or unenforceability affect the validity or enforceability of such provision, or the application thereof, in any other jurisdiction. 

  
 6. 

 22. Counterparts. This Note may be executed in any number of counterparts,
including via facsimile or electronic transmission, each of which shall be an original, but all of which together shall constitute one instrument. 

  
 7. 

 IN WITNESS
WHEREOF, the Company has caused this CONVERTIBLE PROMISSORY NOTE to be executed by its duly authorized officer as of the date first written above.

  

			
	BIONANO GENOMICS, INC.
		
	 By:
	 	 
	 Name:
	 	 R. Erik Holmlin, Ph.D.

	 Title:
	 	 Chief Executive Officer

 Acknowledged and Accepted: 
  

			
	[HOLDER]

			
		
	 By:
	 	 
	 Name:
	 	
	 Title:
	 	

 [SIGNATURE PAGE TO CONVERTIBLE
PROMISSORY NOTE] 

 EXHIBIT B-2 

FORM OF CONVERTIBLE PROMISSORY NOTE AT EACH ADDITIONAL CLOSING 

 THIS NOTE AND THE SECURITIES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES
ACT OF 1933, AS AMENDED (THE “ACT”), AND MAY NOT BE OFFERED, SOLD OR OTHERWISE TRANSFERRED, ASSIGNED, PLEDGED OR HYPOTHECATED UNLESS AND UNTIL REGISTERED UNDER THE ACT OR UNLESS THE COMPANY HAS RECEIVED AN OPINION OF
COUNSEL SATISFACTORY TO THE COMPANY AND ITS COUNSEL THAT SUCH REGISTRATION IS NOT REQUIRED.  
 THE SALE, PLEDGE, HYPOTHECATION OR
TRANSFER OF THIS NOTE AND THE SECURITIES ISSUABLE HEREUNDER IS SUBJECT TO THE TERMS AND CONDITIONS OF A CERTAIN NOTE PURCHASE AGREEMENT BY AND BETWEEN THE HOLDER AND THE COMPANY. COPIES OF SUCH AGREEMENT MAY BE OBTAINED UPON WRITTEN REQUEST TO THE
SECRETARY OF THE COMPANY. 
 THIS NOTE (AND ALL PAYMENT AND ENFORCEMENT PROVISIONS HEREIN) (THE
“NOTE”) IS AN UNSECURED OBLIGATION OF THE COMPANY AND IS SUBJECT TO THE TERMS OF A SUBORDINATION AGREEMENT DATED AS OF FEBRUARY [7], 2018, BY AND AMONG THE COMPANY, THE HOLDER, WESTERN ALLIANCE BANK AND OTHER PARTIES
THERETO (THE “SUBORDINATION AGREEMENT”). IN THE EVENT OF ANY INCONSISTENCY BETWEEN THIS NOTE AND THE SUBORDINATION AGREEMENT, THE TERMS OF THE SUBORDINATION AGREEMENT SHALL CONTROL. 

BIONANO GENOMICS, INC. 

CONVERTIBLE PROMISSORY NOTE 
  

			
	 $[___________]
	  	 [____________], 2018

San Diego, California

 FOR VALUE RECEIVED,
BIONANO GENOMICS, INC., a Delaware corporation (the “Company”), hereby promises to pay to the order of [______________] (the
“Holder”), the principal sum of up to $[_________] (the “Loan Amount”), together with accrued and unpaid interest thereon, each due and payable on the date and in the manner set forth below. 

This Note is part of a series of similar notes (collectively, the “Notes”) issued pursuant to the terms of that
certain Note Purchase Agreement dated as of February [8], 2018, among the Company and the Investors listed on the Schedule of Investors attached thereto as Exhibit A (as may be amended from time to time, the “Purchase
Agreement”). Capitalized terms used and not otherwise defined herein shall have the meanings given them in the Purchase Agreement. 

1. Maturity Date. Unless converted into equity securities of the Company or repaid pursuant to Sections 5 or 6 hereof, subject
to the provisions of Sections 6 and 9 below, the entire outstanding principal balance and all unpaid accrued interest hereof shall, upon written election of the Requisite Investors, become fully due and payable to the Holder on September 30,
2018, or such later date as is approved by the Requisite Investors (the “Maturity Date”). 

  
 1. 

 2. Interest. Interest shall accrue on the outstanding principal amount hereof from
the date of this Note until payment or conversion in full, which interest shall be payable at the rate of 8% per annum or the Highest Lawful Rate (as defined below), whichever is less. Interest shall be due and payable on the Maturity Date, and
shall be calculated on the basis of a 365-day year for the actual number of days elapsed. 

3. Payment. Unless the indebtedness outstanding under this Note is converted in accordance with Sections 5 hereof, payment shall
be made in lawful money of the United States to the Holder at the Company’s principal offices or, at the option of the Holder, at such other place in the United States as Holder shall have designated by written notice to the Company. All
payments shall be applied first to accrued interest and thereafter to principal and shall be made pro rata among all holders of Notes. 

4. Prepayment. Except as provided in Sections 6 and 9, prepayment by the Company of principal or accrued interest outstanding
under this Note may be made only with the prior written consent of the Requisite Investors, and provided that any such prepayment shall be made on a pro rata basis among all of the Notes. 

5. Conversion. 

5.1 Conversion at Qualified Financing. Upon the closing of a Qualified Financing (as defined below) before
the Maturity Date, if this Note has not been prepaid or converted prior to closing of the Qualified Financing, then all unpaid principal and accrued interest outstanding under this Note (the “Conversion Amount”) shall
automatically convert into that number of shares of the Preferred Stock sold by the Company in the Qualified Financing as is equal to the quotient of (x) the Conversion Amount as of the date immediately prior to the initial closing of such
Qualified Financing divided by (y) the Conversion Price (as defined below), and on the other terms and conditions provided to investors in the Qualified Financing; provided, however, that such Preferred Stock issued to the Holder shall
be participating Preferred Stock (for clarity, with participation by the holders of such Preferred Stock being on a pro rata and as-converted basis, together with the holders of the Company’s Common Stock
and any other series of the Company’s participating Preferred Stock, in any remaining proceeds following the payment of all liquidation preferences) and the liquidation preference of each share of such Preferred Stock shall be the greater of
(a) the liquidation preference of the Preferred Stock sold by the Company in the Qualified Financing and (b) two and one quarter times the original issue price of such Preferred Stock. “Qualified Financing” shall
mean the first equity financing following the date of this Note involving the sale by the Company of its Preferred Stock in which the Company receives an aggregate of at least $15,000,000 in cumulative gross proceeds, excluding conversion of the
Conversion Amount under this Note and all other Notes in connection with such financing. “Conversion Price” shall mean 80% of the lowest per share cash purchase price of the Preferred Stock sold by the Company in the
Qualified Financing. 
 5.2 Conversion at Initial Public Offering. If at any time prior to the Maturity Date
the Company completes an initial public offering of its Common Stock pursuant to an effective registration statement under the Securities Act of 1933, as amended (the “IPO”), if this Note has not been prepaid or converted
prior to the closing of the IPO, then the Company 

  
 2. 

 
shall provide to the Holder at least 10 days written notice prior to the closing of the IPO, and the Conversion Amount shall automatically convert into that number of shares of Common Stock as is
equal to the quotient of (x) the Conversion Amount as of the date immediately prior to the closing of the IPO divided by (y) 80% of the per share cash purchase price of the Common Stock to the public in the IPO. 

5.3 Optional Conversion at Maturity Date. If this Note has not been previously converted pursuant to a Qualified
Financing or an IPO, then, effective as of the Maturity Date, upon written election of the Requisite Investors, the Conversion Amount shall automatically convert into a number of shares of Series D-2 Preferred
(as defined below) as is equal to the quotient of (x) the Conversion Amount as of the Maturity Date divided by (y) the price per share equal to $60,000,000 divided by the aggregate number of outstanding shares of the Company’s Common
Stock (the “Common Stock”) as of the Maturity Date (assuming, for purposes of calculating such number of outstanding shares, conversion of all securities convertible into Common Stock and exercise of all outstanding options
and warrants (whether vested or unvested) and including all shares reserved for future issuance under authorized but unissued options, but excluding the shares of equity securities of the Company issuable upon conversion of the Notes). Any
election by the Requisite Investors to convert the Notes pursuant to this Section 5.3 will be made in writing and delivered to the Company at least five days prior to the Maturity Date. “Series D-2 Preferred” shall mean a newly designated series of Preferred Stock of the Company with rights and preferences equivalent to the most senior then outstanding series of Preferred Stock, which shall be
participating Preferred Stock (for clarity, with participation by the holders of such preferred stock being on a pro rata and as-converted basis, together with the holders of the Company’s Common Stock
and any other series of the Company’s participating Preferred Stock, in any remaining proceeds following the payment of all liquidation preferences) and the liquidation preference of each share of such Preferred Stock shall be equal to two and
one quarter times the original issue price of such Preferred Stock. 
 6. Liquidation Event or Deemed Liquidation Event. If at
any time prior to the Maturity Date there occurs a Liquidation Event or Deemed Liquidation Event (each as defined in the Company’s Eighth Amended and Restated Certificate of Incorporation, as amended (the “Charter”)), if
this Note has not been prepaid or converted prior to the closing of such Liquidation Event or Deemed Liquidation Event, then the Company shall provide to the Holder at least 10 days written notice prior to the closing of such Liquidation Event or
Deemed Liquidation Event, and the Notes will become payable contingent upon and concurrently with the successful closing of such Liquidation Event or Deemed Liquidation Event, for an amount equal to (x) 200% of the outstanding principal amount
of such Note plus (y) all unpaid interest accrued hereunder as of the date of the Liquidation Event or Deemed Liquidation Event. Notwithstanding the foregoing, none of the following events shall be deemed to be a Liquidation Event or Deemed
Liquidation Event: any transaction or series of transactions principally for bona fide equity financing purposes in which cash is received by the Company or any successor or indebtedness of the Company is cancelled or converted or a combination
thereof. 
 7. Reservation of Shares. In case the Company does not, at the time of conversion of this Note, have sufficient
authorized but unissued shares of stock of whatever class or series 

  
 3. 

 
necessary to properly give effect to the conversion of the Note as outlined above, the Company shall promptly (a) give notice to the Holder and (b) subject to receipt of requisite
stockholder approvals (the failure of which shall not be deemed a breach or default under this Note, provided that the Company shall make good faith best efforts to secure such approvals), amend its charter documents so as to provide for adequate
shares of authorized stock to the appropriate class and/or series. 
 8. Termination of Rights. All rights with respect
to this Note shall terminate upon a payment or conversion of the Conversion Amount in full, whether or not this Note has been surrendered. 

9. Default. Each of the following events shall be an “Event of Default” hereunder: 

(a) The Company fails to pay timely any of the principal amount due under this Note on the date the same becomes due and
payable or any accrued interest or other amounts due under this Note on the date the same becomes due and payable; 
 (b)
The Company commits a material breach of the representations, warranties or covenants in the Purchase Agreement or any other Loan Document; 

(c) The Company ceases to conduct or carry out the core business of the Company substantially as now conducted; 

(d) The Company files a petition or action for relief under any bankruptcy, insolvency or moratorium law or any other
law for the relief of, or relating to, debtors, now or hereafter in effect, or makes any assignment for the benefit of creditors or takes any action in furtherance of any of the foregoing; 

(e) An involuntary petition is filed against the Company (unless such petition is dismissed or discharged within 60
days) under any bankruptcy statute now or hereafter in effect, or a custodian, receiver, trustee, assignee for the benefit of creditors (or other similar official) is appointed to take possession, custody or control of any property of the Company;

 (f) The occurrence of an “event of default” or other event or circumstance under any agreement
evidencing any indebtedness for borrowed money which results in the acceleration of, or entitles the holder of such indebtedness to accelerate, the maturity thereof; 

(g) The appointment of a receiver to foreclose the Company’s assets or the initiation of judicial or non-judicial proceedings to enforce collateral rights (such as foreclosure or sale of the Company’s assets) under any agreement evidencing any indebtedness for borrowed money; or 

(h) The dissolution or winding up of the Company, the suspension of its operations, or the taking of any corporate
action to effect any of the foregoing. 
 Upon the occurrence of an Event of Default, all unpaid principal, accrued interest and other
amounts owing hereunder shall automatically, be immediately due, payable and collectible by 

  
 4. 

 
the Holder pursuant to applicable law. Subject to the provisions hereof, the Holder shall have all rights and may exercise any remedies available to it under law, successively or concurrently.

 10. Fractional Shares. No fractional shares shall be issued upon conversion of this Note, and instead any fractional shares
shall be rounded down to the nearest whole share. 
 11. No Impairment. Except and to the extent as waived or consented to by
the Requisite Investors in accordance with Section 17 below, the Company will not, by amendment of the Charter or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of any debt
or equity securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms to be observed or performed hereunder by the Company, but will at all times in good faith assist in the carrying out of all
the provisions of this Note in order to protect the rights of Holder hereunder against impairment. 
 12. Highest Lawful Rate.
Anything herein to the contrary notwithstanding, if during any period for which interest is computed hereunder, the amount of interest computed on the basis provided for in this Note, together with all fees, charges, and other payments or rights
which are treated as interest under applicable law, as provided for herein or in any other document executed in connection herewith, would exceed the amount of such interest computed on the basis of the Highest Lawful Rate (as defined below), the
Company shall not be obligated to pay, and the Holder shall not be entitled to charge, collect, receive, reserve, or take, interest in excess of the Highest Lawful Rate, and during any such period the interest payable hereunder shall be computed on
the basis of the Highest Lawful Rate. “Highest Lawful Rate” means the maximum non-usurious rate of interest, as in effect from time to time, which may be charged, contracted for,
reserved, received, or collected by the Holder in connection with this Note under applicable law. In accordance with this section, any amounts received in excess of the Highest Lawful Rate shall be applied towards the prepayment of principal then
outstanding. 
 13. Security 

13.1 Ranking. Except for the Existing Loan, this Note shall be senior in all respects (including the right of
payment) to all other indebtedness of the Company, now or hereafter existing, provided that this Note will rank pari passu with the other Notes issued by the Company. 

13.2 Senior Indebtedness. The indebtedness evidenced by this Note is subordinated in right of payment to the
prior payment in full of all amounts due in connection with that certain Loan and Security Agreement dated as of March 8, 2016, by and between the Company and Western Alliance Bank, as amended on December 9, 2016, May 2, 2017 and
November 20, 2017 (as may be amended from time to time, the “Existing Loan”). Furthermore, the indebtedness evidenced under this Note is subject to the terms of the Subordination Agreement by and among the Company,
Western Alliance Bank and the Holder, and in the event of any conflict between the terms hereof and the Subordination Agreement, the respective terms of the Subordination Agreement shall prevail. 

14. More Favorable Terms. So long as any portion of the Loan Amount and/or any accrued interest thereon remains unpaid and
outstanding, if after the date hereof the Company 

  
 5. 

 
issues any convertible promissory notes to or enters into any note purchase agreement with any lender having any terms and/or conditions that are, individually or in the aggregate, more favorable
than the terms and conditions granted to the Holder under this Note or any other Loan Document, then the Holder shall have the right to require the Company to amend this Note or any other Loan Document to reflect substantially equivalent terms
and conditions in favor of the Holder. 
 15. Waiver. Subject to any other provision herein or in the other Loan Documents,
the Company hereby waives demand, notice, presentment, protest and notice of dishonor. 
 16. Governing Law. This Note shall
be governed by and construed under the laws of the State of California in all respects as such laws are applied to agreements among California residents entered into and performed entirely within California, without giving effect to conflict of law
principles thereof. 
 17. Successors and Assigns. Neither this Note nor any rights hereunder shall be transferable by the
Holder without the prior written consent of the Company, except to an Affiliate of the Holder in accordance with the terms of the Purchase Agreement. Subject to the foregoing, the provisions of this Note shall inure to the benefit of and be binding
on any successor to the Company and shall extend to any Holder hereof. 
 18. Amendment; Waiver. Any term of this Note may be
amended or waived with the written consent of the Company and the Requisite Investors. Any such amendment or waiver so effected by the Company and the Requisite Investors shall be binding on the Holder. 

19. Agreement to be Bound. As a condition to the conversion of the Note, the Holder, if requested by the Company, shall agree in
writing to be fully bound by any purchase agreement or investors rights, stockholders, voting or similar agreements applicable to the holders of the Company’s capital stock. 

20. Expenses; Attorney’s Fees. Each party shall pay all costs and expenses that it incurs with respect to the negotiation,
execution and delivery of the Agreement. If any action at law or in equity (including arbitration) is necessary to enforce or interpret the terms of any of the Loan Documents, the prevailing party shall be entitled to reasonable attorneys’
fees, costs and necessary disbursements in addition to any other relief to which such party may be entitled. 
 21.
Severability. Each of the provisions of this Note is severable. If any such provision is held to be or becomes illegal, invalid or unenforceable in any respect under the law of any jurisdiction, it shall have no effect on any other provisions
of this Note and (a) the parties shall use their reasonable efforts to replace such provision with a suitable and equitable provision in order to carry out as closely as is possible, so far as may be valid and enforceable, the intent and
purpose of such illegal, invalid or unenforceable provision and (b) the remainder of this Note and the application of such provision to other persons or circumstances shall not be affected by such illegality, invalidity or unenforceability, nor
shall such illegality, invalidity or unenforceability affect the validity or enforceability of such provision, or the application thereof, in any other jurisdiction. 

  
 6. 

 22. Counterparts. This Note may be executed in any number of counterparts,
including via facsimile or electronic transmission, each of which shall be an original, but all of which together shall constitute one instrument. 

  
 7. 

 IN WITNESS
WHEREOF, the Company has caused this CONVERTIBLE PROMISSORY NOTE to be executed by its duly authorized officer as of the date first written above.

  

			
	BIONANO GENOMICS, INC.

 
			
		
	By: 	 	 

 
			
	Name: R. Erik Holmlin, Ph.D.
	Title: Chief Executive Officer

 Acknowledged and Accepted: 

[HOLDER] 
  

			
	By: 	 	 

			
	Name:	 	
	 Title:
	 	

 [SIGNATURE PAGE TO CONVERTIBLE
PROMISSORY NOTE] 

 EXHIBIT C 

LIST OF APPROVED ADDITIONAL INVESTORS 

 

					
	 Investor
	  	Maximum
Approved
Participation
Amount	 
	 Full Succeed International Limited
	  	$	853,880	 
	 Novartis Bioventures Ltd.
	  	$	803,857	 
	 Han Cao
	  	$	391,272	 
	 Ascender Prosperity Capital Co., Ltd
	  	$	341,551	 
	 Innovation Valley Partners, LP
	  	$	209,320	 
	 AriMed International Ltd.
	  	$	179,315	 
	 HybriBio Limited
	  	$	170,780	 
	 Shrewsbury Capital Partners LLC
	  	$	72,035	 
	 BVP GP, LLC
	  	$	12,340	 
	 Steve Chazen
	  	$	12,262	 
	 Ben Franklin Technology Partners
	  	$	11,408	 
	 Peter B. Dervan
	  	$	6,000	 
	 Michael Kochersperger
	  	$	1,023	 

 EXHIBIT D 

FORM OF SUBORDINATION AGREEMENT 

Please see attachedEX-10.37

 Exhibit 10.37 

BIONANO GENOMICS, INC. 

FIRST AMENDMENT TO NOTE PURCHASE AGREEMENT 

This First Amendment (this “Amendment”) to that certain Note Purchase Agreement, dated as of
February 9, 2018 (the “Purchase Agreement”), by and among BIONANO GENOMICS, INC., a Delaware corporation (the “Company”), and the
persons and entities named on the Schedule of Investors attached thereto (the “Investors”), is made and entered into as of April 2, 2018 by and among the Company and the Investors listed on the signature pages to this
Amendment. Capitalized terms used and not otherwise defined herein shall have the respective meanings given to them in the Purchase Agreement. 

RECITALS 

WHEREAS, the Company and the Investors have previously entered into the Purchase
Agreement; 
 WHEREAS, Section 10(g) of the Purchase Agreement provides that no
amendment of any provision of the Purchase Agreement shall be effective unless in writing and approved by (i) the Company and (ii) the Investors holding at least 60% of the then-outstanding and unpaid principal and interest under all Notes
(the “Requisite Investors”); and 
 WHEREAS, the undersigned
constitute the Company and the Requisite Investors. 
 AGREEMENT 

NOW, THEREFORE, in consideration of the foregoing and the promises and
covenants contained in this Amendment and in the Purchase Agreement, and for other good and valuable consideration, the receipt of which is hereby acknowledged, the parties to this Amendment agree as follows: 

1. Recitals. The reference to $15,960,000 in the paragraph located under the heading “Recitals” in
the Purchase Agreement shall be replaced with $18,372,132. 
 2. Section 1(a). The reference to “each
Additional Closing” in Section 1(a) of the Purchase Agreement shall be replaced with “the Additional Closing.” 

3. Section 1(b) of the Purchase Agreement. Section 1(b) of the Purchase Agreement is hereby amended
and restated as follows: 
 “(b) Additional Closing. If the aggregate principal amount of the
Notes purchased at the First Closing is less than $18,372,132, then at any time on or before the earlier of the consummation of a Qualified Financing (as defined in the Notes), the filing of a public registration statement with respect to
an IPO (as defined in the Notes), Liquidation Event or Deemed Liquidation Event (each as defined in the Notes), or July 31, 2018 (the “Outside Date”), or such later date as is approved by the Investors holding at least 60% of the
then-outstanding and unpaid principal and interest under all Notes (the “Requisite Investors”), the Company may sell up to the balance of the 

 
authorized Notes not sold at the First Closing in one additional closing (the “Additional Closing” and each of the First Closing and the Additional Closing, a
“Closing”) to Chengdu Berry Genomics Technology Co., Ltd. or its Affiliate (“Berry”), up to the amount set forth on EXHIBIT C attached hereto. In addition to the other
closing conditions set forth in this Agreement, the Additional Closing with Berry shall be subject to (i) Berry’s receipt of internal approval and authorization for the transactions contemplated under the Purchase Agreement,
(ii) Berry’s receipt of any and all approvals or notices of record filing from the Ministry of Commerce, State Administration of Foreign Exchange and the National Development and Reform Commission of China, relating to the
transactions contemplated under the Purchase Agreement, and (iii) no material adverse effect relating to the Company’s business, properties, assets, or operations, taken as a whole, existing at the time of the Additional Closing with
Berry. Upon signing a counterpart signature page to this Agreement and its purchase of a Note at the Additional Closing, Berry shall become a party to this Agreement and shall be deemed to be an “Investor” for all
purposes under this Agreement, and the Schedule of Investors attached hereto shall be amended to reflect the amount Berry has agreed to lend the Company in the column entitled “Additional Closing Loan Amount” (such amount and the
First Closing Investors’ “First Closing Loan Amount,” a “Loan Amount”). The loan made at the Additional Closing shall be made on the terms and conditions set forth in this Agreement, and the representations and
warranties of the Company set forth in Section 3 hereof and the representations and warranties of the Investors set forth in Section 4 hereof shall speak as of the date of the Additional Closing. Any Note issued pursuant to this
Section 1(b) shall be deemed to be a “Note” for all purposes under this Agreement. On the Additional Closing Date (as defined below), Berry shall lend to the Company at the Additional Closing the amount set forth opposite its name
under the column entitled “Additional Closing Loan Amount” on the Schedule of Investors attached hereto (as may be amended as described above) against the issuance and delivery by the Company of a Note for such Loan Amount.”

 4. Section 2(a) of the Purchase Agreement. The second sentence of Section 2(a) of the Purchase
Agreement is hereby amended and restated as follows: 
 “(a) Closing Dates. The Additional
Closing shall be held at any time on or before the Outside Date as the Company and Berry shall agree (such date, the “Additional Closing Date”).” 

5. Section 10(m) of the Purchase Agreement. A new section 10(m) shall be inserted following
Section 10(l) of the Purchase Agreement, which shall read as follows: 
 “(m) Waiver of
Conflicts. Each party to this Agreement acknowledges that Cooley LLP (“Cooley”), outside general counsel to the Company, has in the past performed and is or may now or in the future represent one or more Investors or
their affiliates in matters unrelated to the transactions contemplated by this Agreement (the “Financing”), including representation of such Investors or their affiliates in matters of a similar nature to the Financing. The
applicable rules of professional conduct require that Cooley inform the parties hereunder of this representation and obtain their consent. Cooley has served as outside general counsel to the Company and has negotiated the

 
terms of the Financing solely on behalf of the Company. The Company and each Investor hereby (a) acknowledge that they have had an opportunity to ask for and have obtained
information relevant to such representation, including disclosure of the reasonably foreseeable adverse consequences of such representation; (b) acknowledge that with respect to the Financing, Cooley has represented solely the Company, and
not any Investor or any stockholder, director or employee of the Company or any Investor; and (c) gives its informed consent to Cooley’s representation of the Company in the Financing.” 

6. List of Exhibits and Exhibit Pages. The reference to “each Additional Closing” under the headings
“List of Exhibits” and “Exhibit B-2” in the Purchase Agreement shall be replaced with “the Additional Closing.” 

7. Exhibit C to the Purchase Agreement. Exhibit C to the Purchase Agreement is hereby amended and restated in
the form attached to this Amendment as Exhibit C. 
 8. Effect of Amendment. Except as expressly modified by
this Amendment, the Purchase Agreement shall remain unmodified and in full force and effect. 
 9. Governing
Law. This Amendment shall be governed by and construed under the laws of the State of California in all respects as such laws are applied to agreements among California residents entered into and performed entirely within California, without
giving effect to conflict of law principles thereof. 
 10. Counterparts. This Amendment may be executed in
any number of counterparts, each of which shall be an original, but all of which together shall constitute one instrument. Signatures delivered by facsimile or electronic transmission shall have the same effect as originals. 

[Remainder of Page Intentionally Left Blank] 

 IN WITNESS WHEREOF, the
undersigned has executed this FIRST AMENDMENT TO NOTE PURCHASE AGREEMENT as of the date first written above. 

 

			
	BIONANO GENOMICS, INC.
		
	By: 	 	/s/ Erik Holmlin

			
	Name: Erik Holmlin
	Title: Chief Executive Officer

 IN WITNESS WHEREOF, the
undersigned has executed this FIRST AMENDMENT TO NOTE PURCHASE AGREEMENT as of the date first written above. 

 

			
	INVESTOR:
	
	LC HEALTHCARE FUND I, L.P.
		
	By: 	 	/s/ Jafar Wang
	Name: Jafar Wang
	Title: Managing Director

 IN WITNESS WHEREOF, the
undersigned has executed this FIRST AMENDMENT TO NOTE PURCHASE AGREEMENT as of the date first written above. 

 

			
	INVESTOR:
	
	ROSY SHINE LIMITED
		
	By: 	 	/s/ Hao Ouyang
	Name: Hao Ouyang
	Title: Director

 IN WITNESS
WHEREOF, the undersigned has executed this FIRST AMENDMENT TO NOTE PURCHASE AGREEMENT as of the date
first written above and shall become a party to the Purchase Agreement and that certain Subordination Agreement, dated as of February 9, 2018, by and among Western Alliance Bank and the Creditors named therein (the “Subordination
Agreement”). 
 The representations and warranties contained in Section 4 of the Purchase Agreement shall
be true and correct as to the undersigned as of the date of the Additional Closing with the undersigned. 
 In connection
with the Additional Closing to with the undersigned, the undersigned agrees to lend to the Company the principal amount set forth below (the “Loan Amount”) against issuance by the Company of a Note, in the form attached to
the Purchase Agreement as Exhibit B-2, evidencing such Loan Amount. Upon the payment of the Loan Amount to the Company, the undersigned shall become (i) an “Investor” for all purposes under the
Purchase Agreement and (ii) a “Creditor” for all purposes under the Subordination Agreement. Receipt of the Note by the undersigned shall constitute acceptance of and agreement to all of the terms and conditions contained in the Note.

  

			
	INVESTOR:
	
	 CHENGDU BERRY GENOMICS

TECHNOLOGY CO., LTD

		
	By: 	 	/s/ Daixing Zhou
	Name: Daixing Zhou
	Title: Chief Executive Officer

 EXHIBIT C 

LIST OF APPROVED ADDITIONAL INVESTORS 
  

					
	 Investor
	  	Maximum
Approved
Participation
Amount	 
	 Chengdu Berry Genomics Technology Co., LTD
	  	$	5,000,000

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00285-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00285-of-00352.parquet"}]]